Arulselvan Angel Jenifer, Manimuthu Mani Sankar, Narayanaswamy Radhakrishnan
Biochemistry, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (Deemed to be University), Chennai, IND.
Cureus. 2024 Feb 8;16(2):e53886. doi: 10.7759/cureus.53886. eCollection 2024 Feb.
Background (Stinging nettle)has been reported to exhibit various pharmacological activities. In the present study, we aimed to evaluate 24 selected constituents of as potent inhibitory agents of human carbonic anhydrase II (hCA-II), human 11 beta-hydroxysteroid dehydrogenases type 1 (h11beta-HSD1), and human dual specificity phosphatase (hCDC25B) using method. Methodology The 24 selected constituents of (Stinging nettle) were studied on the docking behavior of hCA-II, h11beta-HSD1, and hCDC25B by using the Webina docking method. In addition to docking, toxicity analysis was also performed using the pkCSM free web server, respectively. Results Toxicity analysis has shown that six ligands (25%) of (Stinging nettle) are predicted to have hERG II (Human ether-a-go-go-related gene) inhibition activity. The docking analysis showed that afzelin, stigmastane-3, 6-diol, and astragalin of have shown the maximum binding energy (-7.2, -9.5, and -8.5 kcal/mol) with the hCA-II, h11beta-HSD1 and hCDC25B, respectively. Conclusions Thus, the current finding provides new knowledge about the 24 selected ligands of (Stinging nettle) as potent inhibitory agents of human carbonic anhydrase II (hCA-II), human 11 beta-hydroxysteroid dehydrogenases type 1 (h11beta-HSD1) and human dual specificity phosphatase (hCDC25B).
背景 据报道,(荨麻)具有多种药理活性。在本研究中,我们旨在使用 方法评估荨麻中24种选定成分作为人碳酸酐酶II(hCA-II)、人11β-羟基类固醇脱氢酶1型(h11β-HSD1)和人双特异性磷酸酶(hCDC25B)的有效抑制剂。方法 采用Webina对接方法研究了荨麻中24种选定成分对hCA-II、h11β-HSD1和hCDC25B的对接行为。除对接外,还分别使用pkCSM免费网络服务器进行了毒性分析。结果 毒性分析表明,荨麻的六种配体(25%)预计具有hERG II(人醚-a-去相关基因)抑制活性。对接分析表明,荨麻中的杨梅素、豆甾烷-3,6-二醇和紫云英苷分别与hCA-II、h11β-HSD1和hCDC25B显示出最大结合能(-7.2、-9.5和-8.5千卡/摩尔)。结论 因此,目前的研究结果提供了关于荨麻中24种选定配体作为人碳酸酐酶II(hCA-II)、人11β-羟基类固醇脱氢酶1型(h11β-HSD1)和人双特异性磷酸酶(hCDC25B)有效抑制剂的新知识。